Fabry Disease Therapy: State-of-the-Art and Current Challenges

Abstract excerpt

Fabry disease (FD) is a lysosomal storage disorder caused by mutations of the GLA gene that lead to a deficiency of the enzymatic activity of α-galactosidase A. Available therapies for FD include enzyme replacement therapy (ERT) (agalsidase alfa and agalsidase beta) and the chaperone migalastat. Despite the large body of literature published about ERT over the years, many issues remain unresolved, such as the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carbohydrate Chemistry and Synthesis
• Share to Cellular transport and secretion
• Share to Lysosomal Storage Disorders Research